Biogen Presents New Data From Alzheimer's Study; Lilly Also Releases Alzheimer's Drug Data

Biogen shows its drug was able to demonstrate a reduction of beta amyloid plaques in the brain, but has not yet achieved statistical significance in improving cognition. Lilly's results were similarly mild.